A new review in Genes & Diseases highlights how
colorectal cancer rewires its use of nutrients to support growth, evade immune defenses and withstand treatment. By connecting these metabolic changes with tumor behavior, the article outlines potential routes toward
earlier detection and more personalized therapies.
The review, prepared by a team from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, and Ganzhou Cancer Hospital, Gannan Medical University, examines how altered
glucose, lipid and amino acid metabolism shapes colorectal cancer. Its central message is that metabolism does more than supply energy: it helps determine how tumors survive, spread and respond to medicines.
One prominent feature is the
Warburg effect, in which cancer cells convert glucose into lactate even when oxygen is available. This process supports the production of materials needed for growth. However, colorectal tumors retain
metabolic flexibility, with some cells also drawing on mitochondrial energy production. That adaptability can help explain why blocking a single metabolic pathway may produce different outcomes across tumors.
Lactate emerges as an important player. Beyond being a metabolic byproduct, it can serve as fuel and influence the environment surrounding a tumor. Changes in lactate production and transport are linked to
chemotherapy resistance and
immune suppression, making these processes potential targets for treatment combinations.
The article also describes how altered fat metabolism and dependence on amino acids, including
glutamine, can sustain cancer cells. These pathways interact with cancer-driving signals and the machinery controlling cell survival. Exploiting such dependencies could create opportunities to weaken tumors or restore sensitivity to medicines.
Metabolic changes extend beyond cancer cells. Immune cells and supporting cells compete for nutrients and exchange metabolites within the
tumor microenvironment. These interactions can undermine immune responses and help cancer establish itself in distant organs, including the liver. Understanding this cooperation may reveal ways to interrupt
metastatic growth.
The review points toward
metabolic biomarkers as possible tools for improving early diagnosis and matching treatments to tumor characteristics. It also highlights the potential of combining metabolic interventions with chemotherapy, targeted medicines or immunotherapy.
Uncertainties remain. Metabolic requirements vary between tumor types, disease stages and cellular populations, and many proposed approaches still require
clinical validation. Particular gaps concern cancer stem cells and
microsatellite-stable colorectal cancer, which represents most cases.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Diseases may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)
# # # # # #
Reference
Wen Xiao, Dan Tan, Wen Zeng, Xiaoming Nie, Mingliang Wang, Metabolic reprogramming in colorectal cancer: Mechanisms and therapeutic insights, Genes & Diseases, Volume 14, Issue 1, 2027, 102054,
https://doi.org/10.1016/j.gendis.2026.102054
Funding
National Natural Science Foundation of China
82272633
Jiangxi Provincial Natural Science Foundation (China)
20242BAB20426